Addvise Lab Solutions: Q2’21, 9% EBIT Beat - Redeye

Redeye will likely increase its Base case and forecasts following a Q2 report, beating our EBIT forecasts by 9%. While losing the Covid-related government support present in Q2 2020, an improved sales mix with fewer consumables along with acquisitions led to unchanged reported EBIT. Considering ADDvise is trading at a significant discount to its larger peers, we believe building a track record of solid reports like this is vital.

https://www.redeye.se/research/817666/addvise-q221-9-ebit-beat?utm_source=finwire&utm_medium=RSS